S&P Futures
4,135.00-18.50(-0.45%)Dow Futures
32,989.00-166.00(-0.50%)Nasdaq Futures
14,000.00-35.00(-0.25%)
CymaBay Therapeutics, Inc. (CBAY)
Chart Events
Performance Outlook
| Previous Close | 4.9200 |
| Open | 4.8700 |
| Bid | 0.0000 x 3100 |
| Ask | 0.0000 x 4000 |
| Day's Range | 4.5900 - 4.8902 |
| 52 Week Range | 3.1600 - 9.0600 |
| Volume | 835,390 |
| Avg. Volume | 800,860 |
| Market Cap | 319.23M |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7400 |
| Earnings Date | Aug 09, 2021 - Aug 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.64 |
- GlobeNewswire
CymaBay Therapeutics to Present at Upcoming Investor Conferences
NEWARK, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including SVB Leerink CybeRx Series: “Liver Disease Day” Conference taking place June 17, 2021, the Raymond James Human Health Innovation Conference taking place June 22, 2021 and the Pi
- GlobeNewswire
CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021
NEWARK, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be delivered during The International Liver Congress™ 2021 of the European Association for the Study of Liver (EASL) which will be held online June 23rd – 26th. A presentation1 will be made highlighting the effica
- GlobeNewswire
CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWARK, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of an inducement award to Dennis Kim, MD in connection with his appointment as the company’s Chief Medical Officer. The Compensation Committee of the Board of Directors of CymBay approved the grant of a non-qualified stock option to purchase an aggregate of 390,000 shares of its common stock as an inducement material to Dr. Kim entering into employment with CymaBay in accordance with Nasdaq Listing Rule 5635(c)(4), and is subject to the terms and conditions of the applicable award agreement covering such grant. This stock option grant has an exercise price of $4.37 per share, which is equal to the closing price of CymaBay’s common stock on May 17, 2021, the date of grant for the stock option. The stock option will vest and become exercisable as to 25% of the underlying shares on May 17, 2022, and will vest and become exercisable as to the remaining 75% of the underlying shares in 36 equal monthly installments from May 17, 2022, subject to Dr. Kim’s continued employment with CymaBay on such vesting dates. About CymaBayCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin. Public Relations Contact: Glenn SilverLazar-FINN Partners(973) 818-8198Glenn.silver@finnpartners.com Investor Relations Contact: Hans VitzthumLifeSci Advisors, LLC(617) 430-7578Hans@LifeSciAdvisors.com
